"Note for guidance on the clinical investigation of plasma derived antithrombin products"
It gives some interesting insides.
Could it be that the EMEA just treats ATryn as if it is a substitution for the plasma derived alternative? Ifso, the new guidelines could have lead to the additional questions, wouldn't you think so?